Vicore and Nippon Shinyaku Collaborate for the Development and Commercialization of C21 in Japan
- Vicore Pharma and Nippon Shinyaku have signed an exclusive licensing agreement for the development and commercialization of the former's C21 for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan
- As per the agreement, Vicore retains all the global rights (excl. Japan) to C21 & will obtain $10M upfront, a total of $275M milestones for development and commercialization plus low 20s annual net sales-based tiered royalties while Nippon Shinyaku receives exclusive development & commercialization rights in Japan
- Additionally, the company's P-IIa (AIR) trial revealed improvement in lung function with C21 in previously untreated IPF patients. A global P-IIb (ASPIRE) study is anticipated in H1’24
Ref: Vicore | Image: Vicore
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at email@example.com.